Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6361420, 12 pages
https://doi.org/10.1155/2017/6361420
Research Article

miR-31 Functions as an Oncomir Which Promotes Epithelial-Mesenchymal Transition via Regulating BAP1 in Cervical Cancer

1Laboratory of Molecular Biology, College of Life Science, Jiaying University, Meizhou 514015, China
2Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan 430074, China

Correspondence should be addressed to Nan Wang; nc.ude.uyj@810104102

Received 16 May 2017; Accepted 29 August 2017; Published 11 October 2017

Academic Editor: Stephen H. Safe

Copyright © 2017 Nan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Hildesheim and S. S. Wang, “Host and viral genetics and risk of cervical cancer: a review,” Virus Research, vol. 89, no. 2, pp. 229–240, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Di Leva, G. A. Calin, and C. M. Croce, “MicroRNAs: fundamental facts and involvement in human diseases,” Birth Defects Research Part C—Embryo Today: Reviews, vol. 78, no. 2, pp. 180–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. K. J. Beezhold, V. Castranova, and F. Chen, “Microprocessor of microRNAs: regulation and potential for therapeutic intervention,” Molecular Cancer, vol. 9, article 134, pp. 1–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Gasparini, L. Cascione, M. Fassan et al., “microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers,” Oncotarget, vol. 5, no. 5, pp. 1174–1184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Hayes, P. P. Peruzzi, and S. Lawler, “MicroRNAs in cancer: biomarkers, functions and therapy,” Trends in Molecular Medicine, vol. 20, no. 8, pp. 460–469, 2014. View at Publisher · View at Google Scholar
  7. A. Ventura and T. Jacks, “MicroRNAs and cancer: short RNAs go a long way,” Cell, vol. 136, no. 4, pp. 586–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Liu, L. F. Sempere, H. Ouyang et al., “MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1298–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Sun, F. Yu, Y. Ma et al., “MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1),” The Journal of Biological Chemistry, vol. 288, no. 13, pp. 9508–9518, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Wang, Q. Li, K. Wang et al., “Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer,” Clinical and Translational Oncology, vol. 15, no. 10, pp. 849–854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. P. C. Lin, Y. L. Chiu, S. Banerjee et al., “Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression,” Cancer Research, vol. 73, no. 3, pp. 1232–1244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Wang, Y. Zhou, L. Zheng, and H. Li, “MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A,” Gynecologic Oncology, vol. 134, no. 1, pp. 129–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Polyak and R. A. Weinberg, “Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits,” Nature Reviews Cancer, vol. 9, no. 4, pp. 265–273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Castellanos, N. B. Merchant, and N. S. Nagathihalli, “Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells,” OncoTargets and Therapy, vol. 6, pp. 1261–1267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Bullock, A. E. Sayan, G. K. Packham, and A. H. Mirnezami, “MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression,” Biology of the Cell, vol. 104, no. 1, pp. 3–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. K. H. Ventii, N. S. Devi, K. L. Friedrich et al., “BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization,” Cancer Research, vol. 68, no. 17, pp. 6953–6962, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. L.-H. Fan, L.-N. Tang, L. Yue, Y. Yang, Z.-L. Gao, and Z. Shen, “BAP1 is a good prognostic factor in advanced non-small cell lung cancer,” Clinical & Investigative Medicine, vol. 35, no. 4, pp. E182–E189, 2012. View at Publisher · View at Google Scholar
  19. M. Yu, H. Liang, Z. Fu et al., “BAP1 suppresses lung cancer progression and is inhibited by miR-31,” Oncotarget, vol. 7, no. 12, pp. 13742–13753, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Meng, Z. Ye, R. Cui et al., “MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma,” Clinical Cancer Research, vol. 19, no. 19, pp. 5423–5433, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. L. Cottonham, S. Kaneko, and L. Xu, “miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells,” The Journal of Biological Chemistry, vol. 285, no. 46, pp. 35293–35302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. J. Liu, M. M. Tsai, P. S. Hung et al., “miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma,” Cancer Research, vol. 70, no. 4, pp. 1635–1644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Valastyan, F. Reinhardt, and N. Benaich, “A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis,” Cell, vol. 137, no. 6, pp. 1032–1046, 2009. View at Publisher · View at Google Scholar
  24. H. Nishikawa, W. Wu, A. Koike et al., “BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity,” Cancer Research, vol. 69, no. 1, pp. 111–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. W. Harbour, M. D. Onken, E. D. O. Roberson et al., “Frequent mutation of BAP1 in metastasizing uveal melanomas,” Science, vol. 330, no. 6009, pp. 1410–1413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Wiesner, A. C. Obenauf, R. Murali et al., “Germline mutations in BAP1 predispose to melanocytic tumors,” Nature Genetics, vol. 43, no. 10, pp. 1018–1021, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Jiang, D. He, D. Yang et al., “MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway,” FEBS Letters, vol. 588, no. 11, pp. 2009–2015, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Xia, L. L. P. J. Ooi, and K. M. Hui, “MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer,” Hepatology, vol. 58, no. 2, pp. 629–641, 2013. View at Publisher · View at Google Scholar · View at Scopus